Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$62.12 - $84.15 $985,098 - $1.33 Million
15,858 Added 148.89%
26,509 $1.9 Million
Q1 2024

May 15, 2024

BUY
$65.98 - $77.09 $702,752 - $821,085
10,651 New
10,651 $749,000
Q3 2023

Nov 14, 2023

BUY
$67.52 - $89.42 $7,494 - $9,925
111 Added 3.15%
3,640 $247,000
Q2 2023

Aug 14, 2023

SELL
$73.76 - $85.98 $159,247 - $185,630
-2,159 Reduced 37.96%
3,529 $288,000
Q1 2023

May 15, 2023

BUY
$71.62 - $86.62 $407,374 - $492,694
5,688 New
5,688 $421,000
Q4 2021

Feb 14, 2022

SELL
$456.15 - $525.06 $465,729 - $536,086
-1,021 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$444.87 - $538.88 $847,922 - $1.03 Million
-1,906 Reduced 65.12%
1,021 $494,000
Q2 2021

Aug 16, 2021

BUY
$387.35 - $450.26 $1.13 Million - $1.32 Million
2,927 New
2,927 $1.32 Million
Q4 2020

Feb 16, 2021

SELL
$246.9 - $321.87 $579,968 - $756,072
-2,349 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$232.22 - $282.96 $545,484 - $664,673
2,349 New
2,349 $582,000
Q2 2020

Aug 14, 2020

SELL
$185.43 - $279.56 $670,514 - $1.01 Million
-3,616 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$161.17 - $221.51 $582,790 - $800,980
3,616 New
3,616 $686,000

Others Institutions Holding TECH

About BIO-TECHNE Corp


  • Ticker TECH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,222,600
  • Market Cap $2.59B
  • Description
  • Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures bi...
More about TECH
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.